Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH)
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05955-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Yunze Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Centre, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University), Beij…. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Xanthogranuloma, Juvenile. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Beijing Municipal Administration of Hospitals' Youth Program, Beijing research Ward Project, Research and Transformation Application of Clinical Characteristic Diagnosis and Treatment Techniques in the Capital.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Juvenile xanthogranuloma (JXG) is primarily limited to the skin, and systemic JXG (sJXG) is rarely reported. Reports of sJXG patients with hemophagocytic lymphohistiocytosis (HLH) are particularly rare. Herein, we conducted a retrospective study of children diagnosed with sJXG in the Hematology Centre of Beijing Children's Hospital from Jan. 2016 to Dec. 2021. The clinical features, laboratory parameters, treatments and outcomes of 17 sJXG patients were investigated, including five complicated with HLH. All sJXG-HLH patients had intermittent fever, rash, hepatosplenomegaly, cytopenia and high levels of soluble CD25, but interferon-γ was almost normal. Patients with sJXG-HLH had a younger diagnosis age (P = 0.035) and were more likely to have skin, liver, and spleen involvement than those without HLH (P = 0.029, P = 0.003, P = 0.003, respectively). Corticosteroids and/or ruxolitinib could be used to control the hyperinflammatory status when HLH was diagnosed. The treatment of sJXG varied, including Langerhans cell histiocytosis (LCH)-based chemotherapy and targeted therapy. The overall response rate of sJXG for first-line and second-line chemotherapy was 50.0% (5/10) and 50% (4/8), respectively. Patients with BRAF V600E mutation showed a response to dabrafenib. There was no significant difference in the overall survival and progression-free survival between sJXG patients without and with HLH (P = 0.12 and P = 0.46, respectively). Therefore, LCH-based chemotherapy could serve as an effective treatment for sJXG patients, and dabrafenib, to some extent, showed efficacy in controlling sJXG in patients with BRAF V600E mutation. The prognosis of sJXG-HLH patients seemed to be comparable to patients without HLH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Centre, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University), Beijing, 100045, China.
- Key Laboratory of Major Diseases in Children, Ministry of Education, Nanlishi Road No. 56, Xicheng District, Beijing, 100045, China.
- Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health in Boarding, Beijing, 100045, China.
- Hematology Centre, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University), Beijing, 100045, China. ericlzg70@hotmail.com.
- Key Laboratory of Major Diseases in Children, Ministry of Education, Nanlishi Road No. 56, Xicheng District, Beijing, 100045, China. ericlzg70@hotmail.com.
- Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health in Boarding, Beijing, 100045, China. ericlzg70@hotmail.com.
ORCID-Profile: Yunze Zhao, Tong Zou, Ang Wei, Rui Zhang
Förderung
- Beijing Municipal Administration of Hospitals' Youth Program
- Beijing research Ward Project
- Research and Transformation Application of Clinical Characteristic Diagnosis and Treatment Techniques in the Capital
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals’ Youth Program
Zitieren
APA
Zhao, Y., Zou, T., Wei, A., Ma, H., Lian, H., Wang, D., Li, Z., Wang, T., & Zhang, R. (2024). Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH). Annals of Hematology. https://doi.org/10.1007/s00277-024-05955-x
Vancouver
Zhao Y, Zou T, Wei A, Ma H, Lian H, Wang D, et al. Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH). Annals of Hematology. 2024. doi:10.1007/s00277-024-05955-x
BibTeX
@article{Zhao2024,
author = {Zhao, Yunze and Zou, Tong and Wei, Ang and Ma, Honghao and Lian, Hongyun and Wang, Dong and Li, Zhigang and Wang, Tianyou and Zhang, Rui},
title = {Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH)},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05955-x}
}
EUVIMED